-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.O2.6 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Lymphoid Malignancies
Saturday, December 11, 2021: 12:00 PM-1:30 PM
Hall C1 (Georgia World Congress Center)
Moderators:
Sascha A. Tuchman, MD, The University of North Carolina at Chapel Hill and Monique C. Minnema, MD, Department of Hematology, University Medical Center Utrecht, Utrecht University
Disclosures:
Tuchman: Caelum: Consultancy, Research Funding; Sanofi / Genzyme: Consultancy, Research Funding; Shattuck Labs: Consultancy; Karyopharm: Research Funding; Oncopeptides: Consultancy. Minnema: Celgene: Other: Travel expenses; Janssen: Consultancy, Honoraria; BMS: Consultancy; Kite/Gilead: Consultancy; Alnylam: Consultancy.
12:00 PM

Suzanne Trudel, MD1, Adam D Cohen2, Amrita Y. Krishnan, MD3, Rafael Fonseca4, Andrew Spencer5, Jesús G. Berdeja6, Alexander Lesokhin, MD7, Peter A Forsberg8, Jacob P. Laubach9*, Luciano J. Costa, MD, PhD10, Paula Rodriguez-Otero11*, Rayan Kaedbey12, Joshua Richter, MD13, Maria-Victoria Mateos14, Sheeba K Thomas, MD, MS15, Chihunt Wong16*, Mengsong Li16*, Voleak Choeurng16*, Anjali Vaze16*, Divya Samineni16*, Teiko Sumiyoshi16*, James Cooper16* and Simon J Harrison, MD17

1Princess Margaret Cancer Centre, Toronto, ON, Canada
2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
3City of Hope, Duarte, CA
4Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
5Alfred Health-Monash University, Melbourne, VIC, Australia
6Sarah Cannon Research Institute, Nashville, TN
7Memorial Sloan Kettering Cancer Center, New York, NY
8University of Colorado School of Medicine, Aurora, CO
9Dana-Farber Cancer Institute, Boston, MA
10University of Alabama at Birmingham, Vestavia, AL
11Clínica Universidad de Navarra, Pamplona, Spain
12Jewish General Hospital, McGill University, Montreal, QC, Canada
13Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
14Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain
15The University of Texas MD Anderson Cancer Center, Houston, TX
16Genentech, Inc., South San Francisco, CA
17Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, VIC, Australia

12:15 PM

Amrita Y. Krishnan, MD1, Monique C. Minnema, MD2, Jesús G. Berdeja3, Albert Oriol4*, Niels W.C.J. van de Donk5, Paula Rodriguez-Otero6*, Elham Askari7*, Maria-Victoria Mateos8, Luciano J. Costa, MD, PhD9, Raluca I. Verona10*, Xuewen Ma10*, Suzette Girgis10, Shiyi Yang10*, Brandi W. Hilder10*, Jeffery Russell10*, Jenna D. Goldberg11* and Ajai Chari, MD12*

1City of Hope Comprehensive Cancer Center, Duarte, CA
2University Medical Center Utrecht, Utrecht, Netherlands
3Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN
4Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
5Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Spain
6Clínica Universidad de Navarra, Navarra, Spain
7Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
8University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
9University of Alabama at Birmingham, Birmingham, AL
10Janssen Research & Development, Spring House, PA
11Janssen Research & Development, Raritan, NJ
12Mount Sinai School of Medicine, New York, NY

12:30 PM

Raymond Comenzo, MD1, Giovanni Palladini2, Efstathios Kastritis3*, Monique C. Minnema, MD4, Ashutosh D. Wechalekar5*, Arnaud Jaccard6*, Angela Dispenzieri, MD7, Hans C. Lee, MD8, Vaishali Sanchorawala, MD9, Simon D. Gibbs10*, Peter Mollee11, Chris P. Venner12, Jin Lu, MD13, Stefan Schönland14*, Moshe Gatt15, Kenshi Suzuki, MD, PhD16, Kihyun Kim17*, M. Teresa Cibeira18*, Meral Beksac19*, Edward Libby20, Jason Valent21, Vania Hungria22, Sandy W. Wong, MD23, Michael Rosenzweig24, Naresh Bumma25, NamPhuong Tran26*, Xiang Qin27*, Samer Khaled28*, Jessica Vermeulen29 and Giampaolo Merlini2*

1Tufts Medical Center, Boston, MA
2Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
3Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
5University College London, London, United Kingdom
6Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoge, France
7Mayo Clinic, Rochester, MN
8Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Medicine and Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA
10The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Easter Health Clinical School, Melbourne, VIC, Australia
11Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
12University of Alberta, Edmonton, AB, Canada
13Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing, China
14Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
15Hematology Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel
16Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
17Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
18Amyloidosis and Myeloma Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
19Department of Hematology, Ankara University, Ankara, Turkey
20Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
21Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
22Clinica São Germano, São Paulo, Brazil
23Department of Medicine, University of California San Francisco, San Francisco, CA
24Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
25Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
26Janssen Research & Development, LLC, Los Angeles, CA
27Janssen Research & Development, Spring House, PA
28Janssen Research & Development, Los Angeles, CA
29Janssen Research & Development, Leiden, CB, Netherlands

12:45 PM

Jeffrey A. Zonder, MD 1, Joshua Richter, MD2, Naresh Bumma3, Jason Brayer, PhD, MD4, James E Hoffman, MD5, William I. Bensinger, MD6*, Ka Lung Wu, MD7, Linzhi Xu, PhD8*, Dhruti Chokshi, BS9*, Anita Boyapati, PhD10*, Manish Sharma, MD9*, Karen Rodriguez Lorenc, MD11, Glenn S Kroog, MD9*, Madhav V Dhodapkar, MD12, Suzanne Lentzsch, MD, PhD13*, Dennis Cooper, MD14 and Sundar Jagannath, MD2*

1Karmanos Cancer Institute, Detroit, MI
2Icahn School of Medicine at Mount Sinai, New York, NY
3The Ohio State University Comprehensive Cancer Center, Columbus, OH
4H. Lee Moffitt Cancer Center, Tampa, FL
5University of Miami Health System, Miami, FL
6Swedish Center for Blood Disorders and Stem Cell Transplants, Seattle, WA
7Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
8Biostatistics and Data Management, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
9Clinical Sciences, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
10Precision Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
11Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
12Emory University School of Medicine, Atlanta, GA
13Columbia University Medical Center, New York, NY
14Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

1:00 PM

Ajai Chari, MD1*, Parameswaran Hari2, Nizar J. Bahlis, MD3, Maria-Victoria Mateos4, Niels W.C.J. van de Donk5, Bhagirathbhai Dholaria, MBBS6, Alfred L. Garfall7*, Hartmut Goldschmidt8, K. Martin Kortuem9*, Amrita Y. Krishnan, MD10, Thomas Martin, MD11, Daniel Morillo Giles12*, Albert Oriol13*, Donna E. Reece14, Cesar Rodriguez15, Paula Rodriguez-Otero16*, Jesús F. San-Miguel16, Saad Z. Usmani, MD MBA FACP17, Raluca I. Verona18*, Shun Xin Wang Lin18*, Thomas J. Prior18*, Mark Wade18*, Brendan M. Weiss18, Jenna D. Goldberg19* and Elham Askari12*

1Mount Sinai School of Medicine, New York, NY
2Medical College of Wisconsin, Milwaukee, WI
3Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
4University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
5Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
6Vanderbilt University Medical Center, Nashville, TN
7Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
8University Hospital Heidelberg, Internal Medicine and National Center for Tumor Diseases (NCT), Heidelberg, Germany
9University Hospital Wuerzburg, Wuerzburg, Germany
10City of Hope Comprehensive Cancer Center, Duarte, CA
11University of California San Francisco, San Francisco, CA
12Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
13Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
14Princess Margaret Cancer Centre, Toronto, ON, Canada
15Wake Forest University School of Medicine, Winston-Salem, NC
16Clinica Universidad de Navarra, Navarra, Spain
17Levine Cancer Institute/Atrium Health, Charlotte, NC
18Janssen Research & Development, Spring House, PA
19Janssen Research & Development, Raritan, NJ

1:15 PM

Sagar Lonial, MD, FACP1, Rakesh Popat, MBBS, FRCPath, PhD2*, Cyrille Hulin3*, Sundar Jagannath, MD4*, Albert Oriol5*, Paul G. Richardson, MD6, Thierry Facon7*, Katja Weisel8*, Jeremy T. Larsen9, Monique C. Minnema, MD10, Al-Ola Abdallah, MD11, Ashraf Z. Badros, MD12, Stefan Knop13*, Edward A. Stadtmauer14*, Min Chen15*, Tuong Vi Nguyen15*, Alpesh Amin15*, Elisabeth Kueenburg16*, Teresa Peluso16* and Niels W.C.J. van de Donk17

1Winship Cancer Institute, Emory University, Atlanta, GA
2NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
3Service d'Hématologie Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France
4The Mount Sinai Hospital, New York, NY
5Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
7Service des Maladies du Sang, CHRU de Lille - Hôpital Claude Huriez, Lille, France
8University Medical Center Hamburg-Eppendorf, Hamburg, Germany
9Mayo Clinic Arizona, Phoenix, AZ
10University Medical Center Utrecht, Utrecht, Netherlands
11University of Kansas Medical Center, Kansas City, KS
12Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD
13Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
14University of Pennsylvania, Philadelphia, PA
15Bristol Myers Squibb, Princeton, NJ
16Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
17Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands

*signifies non-member of ASH